Post Profile






High-cost drug helps slash cholesterol in sick patients

A new cholesterol-lowering drug evolocumab helps high-risk patients reduce the likelihood of a heart attack or stroke, but its high cost raises questions about how many patients will benefit, researchers said Friday. The results of a two-year clinical trial on the drug sold as Repatha by Amgen Phamaceuticals that costs more than $14,000 a year were released at the American College of Cardiology annual conference in the US capital.
read more

share

Related Posts


A POST-STATIN WORLD? Tests of Cholesterol Drugs Offer Hope of Reducing Heart Attacks and Strokes. …

US Politics / Conservative : Instapundit

A POST-STATIN WORLD? Tests of Cholesterol Drugs Offer Hope of Reducing Heart Attacks and Strokes. “A new class of experimental cholesterol drugs might sharply reduce the risk of heart attacks and strokes, researchers reported on Sun...

Medical News Today: New cholesterol-lowering drug 'could halve risk of heart attack, stroke'

Health : Medical News Today

A study reveals how a new drug called evolocumab reduced LDL cholesterol in patients by more than 60% and more than halved their risk of cardiovascular events, such as stroke.

Drug which cuts 'bad' cholesterol can help prevent heart attacks and strokes

Health : The Guardian: Health

Trial of 27,000 patients found that those taking drug evolocumab saw their levels of low-density lipoprotein cholesterol fall A new drug can prevent heart attacks and strokes by cutting bad cholesterol levels, scientists have found....

First heart attack or stroke risk decreased in patients using cholesterol lowering statins: Study

Health : Bel Marra Health

First heart attack or stroke risk is decreased in patients using cholesterol-lowering drugs known as statins. Statins were effective at reducing the risk of death, heart attack, and stroke among people with various risk factors. The...

Amgen cholesterol drug cuts heart attack, stroke risk more than 20 percent: study

Health : Reuters: Health

WASHINGTON (Reuters) - Amgen Inc's Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clear clinical benefit beyond its ability to slash "bad" LDL cholesterol le...

Comments


Copyright © 2016 Regator, LLC